has acquired the molecular imaging development portfolio of Bayer Pharma AG. The terms of the deal were not disclosed, however the deal involves certain milestone and royalty payments.
The acquisition is being made through it's newly created subsidiary - Piramal Imaging SA. The portfolio includes rights to florbetaben, that helps detect beta-Amyloid plaque deposition in the brain – an indication of probable Alzheimer’s disease.
Florbetaben is a radioactive compound being developed by Bayer as an imaging agent for the detection of beta-Amyloid plaque deposition in the brain, which is the pathological hallmark of disease in probable Alzheimer’s disease patients.